Clinical trials: ILD
Interstitial Lung Diseases
Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
The purpose of this multi-centered, NIH-sponsored study is to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).
- Trial name
- NCT04855305
- Testing
- Hyperpolarized 129Xe
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
COPD, Interstitial Lung Disease
Autologous Stem Cell Treatment for Chronic Lung Disease Study
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day.
- Trial name
- NCT03044431
- Testing
- Cell therapy
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Lung Institute
Transplant; Failure, Kidney, Renal Disease, End Stage
Oral Paricalcitol in Kidney Transplant Recipients
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this…
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- NCT00587158
- Testing
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Idiopathic Pulmonary Fibrosis, Diarrhoea
A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib
This is an observational, non-interventional, and prospective post authorization safety study (PASS) that will describe the real-world proportion of patients that achieve nintedanib-associated diarrhoea control after 12 weeks of…
- Trial name
- NCT06200714
- Testing
- Nintedanib
- Where
- 8 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary…
- Trial name
- NCT04419558
- Testing
- Pamrevlumab
- Where
- 157 sites in United States, Argentina and 23 more
- Volunteers
- 372 people
- Sponsor
- Kyntra Bio
Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA)
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
The purpose of this study is to determine whether plasma exchange as well as immunosuppressive therapy are effective in reducing death and end-stage renal disease (ESRD).
- Trial name
- PEXIVAS (NCT00987389)
- Testing
- Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose]
- Where
- 98 sites in United States, Australia and 13 more
- Volunteers
- 704 people
- Sponsor
- University of Pennsylvania
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
The purpose of this research study is to learn about the safety of transplanting lungs obtained from non-heart-beating donors (NHBDs) that have been ventilated (attached to a breathing machine or ventilator to deliver oxygen) and…
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- NCT01615484
- Testing
- Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Lung Diseases, Interstitial
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study.
- Trial name
- NCT05321082
- Testing
- BI 1015550
- Where
- 400 sites in United States, Argentina and 43 more
- Volunteers
- 1,178 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.
The primary objective is to investigate safety and tolerability of BI 1015550 in patients with IPF. The secondary objectives are to evaluate the pharmacokinetics (PK) of BI 1015550 in patients with IPF.
- Trial name
- NCT03422068
- Testing
- BI 1015550
- Where
- 11 sites in Denmark, Finland and 5 more
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Pulmonary Disease, Chronic Obstructive
Advancing Symptom Alleviation With Palliative Treatment
Chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD), and interstitial lung disease (i.e., pulmonary fibrosis) are common serious illnesses.
- Conditions
- Heart Failure, Pulmonary Disease, Chronic Obstructive, Emphysema, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- ADAPT (NCT02713347)
- Testing
- ADAPT Intervention
- Where
- 2 sites in United States
- Volunteers
- 306 people
- Sponsor
- VA Office of Research and Development
Idiopathic Pulmonary Fibrosis
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic…
- Trial name
- BUILD OL (NCT00631475)
- Testing
- Bosentan
- Volunteers
- 128 people
- Sponsor
- Actelion
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
The primary objective of this study is to establish the feasibility and safety of infusions of placental Mesenchymal Stem Cells (MSC) from related or unrelated HLA identical or HLA mismatched donors in the treatment of Idiopathic…
- Trial name
- MSC in IPF (NCT01385644)
- Testing
- Placental MSC
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- The Prince Charles Hospital
Covid19, Post-acute COVID-19 Respiratory Disease
LYT-100 in Post-acute COVID-19 Respiratory Disease
This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory…
- Trial name
- NCT04652518
- Testing
- LYT-100
- Where
- 31 sites in United States, Argentina and 6 more
- Volunteers
- 185 people
- Sponsor
- PureTech
Idiopathic Pulmonary Fibrosis, Hypoxemia
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.
- Trial name
- NCT02846324
- Testing
- GBT440
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Global Blood Therapeutics
Idiopathic Pulmonary Fibrosis
Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic…
- Trial name
- NCT05130970
- Testing
- Garadacimab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 81 people
- Sponsor
- CSL Behring
Graft Dysfunction, Interstitial Fibrosis
Novartis Everolimus Transition
Transition from tacrolimus based triple therapy with Mycophenolate Mofetil (MMF) and steroids in stable renal transplant patients to low intensity tacrolimus, everolimus and prednisone will be associated with improvement in…
- Trial name
- NCT02096107
- Testing
- Everolimus, Standard of Care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Langerhans Cell Histiocytosis
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.
- Trial name
- NCT02425904
- Testing
- Clofarabine
- Where
- 15 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Idiopathic Pulmonary Fibrosis
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).
Assess the safety of CHF10067 (study drug) and any side effects that might be associated with it. The study also evaluated how much of the study drug gets into the bloodstream and how long the body takes to remove it.
- Trial name
- NCT05513950
- Testing
- CHF10067 starting dose -- 1000mg (Cohort A), CHF10067 intermediate dose -- 2000mg (Cohort B), CHF10067 high dose -- 3000mg (Cohort C)
- Where
- 9 sites in North Macedonia, Ukraine and 1 more
- Volunteers
- 52 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Idiopathic Pulmonary Fibrosis
Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
This is a phase IV, twelve week, open label, randomized, parallel group study to assess safety and tolerability of combined treatment with nintedanib and pirfenidone.
- Trial name
- NCT02579603
- Testing
- Nintedanib, Pirfenidone
- Where
- 23 sites in United States, Canada and 4 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT01629667
- Testing
- Tralokinumab
- Where
- 45 sites in United States, Australia and 4 more
- Volunteers
- 409 people
- Sponsor
- MedImmune LLC